N@N

FFBC, DGX, AGP, HSP, NKTR, AET Are Seasonally Ripe To Go Up In the Next Five Weeks

^{Published on 2011-10-31 08:00:17 - WOPRAI}
 

October 31, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of FIRST FINANCIAL BANCORP (NASDAQ:FFBC), QUEST DIAGNOSTICS INCORPORATED (NYSE:DGX), AMERIGROUP CORP (NYSE:AGP), HOSPIRA INC (NYSE:HSP), NEKTAR THERAPEUTICS (NASDAQ:NKTR), AETNA INC (NYSE:AET) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Up:

     Symbol     Company                             Expected Return     Odds                    By The Following Date
     FFBC       FIRST FINANCIAL BANCORP             2.82%               100.00% (11 of 11)      Friday, November 11th 2011
     DGX        QUEST DIAGNOSTICS INCORPORATED      1.77%               85.71% (12 of 14)       Wednesday, November 2nd 2011
     AGP        AMERIGROUP CORP                     6.33%               88.89% (8 of 9)         Friday, November 11th 2011
     HSP        HOSPIRA INC                         3.12%               100.00% (7 of 7)        Friday, November 4th 2011
     NKTR       NEKTAR THERAPEUTICS                 12.93%              90.91% (10 of 11)       Friday, December 9th 2011
     AET        AETNA INC                           11.56%              91.67% (11 of 12)       Tuesday, December 13th 2011

QUEST DIAGNOSTICS INCORPORATED (NYSE:DGX) - Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. It offers patients and physicians the access to diagnostic testing services through its network of laboratories and patient service centers; and interpretive consultation services. The company provides commercial clinical testing services, including routine clinical testing for blood chemistries, complete blood cell counts, urinalyses, pregnancy and other prenatal tests, routine microbiology testing, prescription drug monitoring, alcohol and other substance-abuse tests, and allergy tests; gene-based and esoteric testing; and anatomic pathology services, as well as risk assessment services for the life insurance industry. It also develops and integrates clinical connectivity and data management solutions for healthcare organizations, physicians, and clinicians through its Care360 suite of products; and offers Centergy Data Exchange and the ChartMaxx electronic document management system to hospitals. In addition, the company provides central laboratory testing services in connection with clinical research trials on new drugs, vaccines, and medical devices; and clinical testing to employers for the detection of employee use of drugs-of-abuse. Further, it develops and manufactures products that enable healthcare professionals to make healthcare diagnoses, including HerpeSelect ELISA tests that detect patient antibodies to certain types of herpes simplex virus, and sells to academic medical centers, hospitals, and commercial laboratories; White Blood Cell Analyzer for performing whole-blood test on finger-stick samples; and InSure fecal immunochemical test for screening for colorectal cancer. The company was founded in 1967 and is headquartered in Madison, New Jersey.

AMERIGROUP CORP (NYSE:AGP) - AMERIGROUP Corporation operates as a multi-state managed healthcare company. It focuses on serving people, who receive healthcare benefits through publicly funded health care programs, including Medicaid, Childrens Health Insurance Program (CHIP), Medicaid expansion programs, and Medicare Advantage. The companys Medicaid program makes federal matching funds available to various states for the delivery of healthcare benefits to eligible individuals, as well as allows each state to establish its own eligibility standards, benefits package, payment rates, and program administration under broad federal guidelines. AMERIGROUP also provides CHIP, a federal and state funded program that offers health care coverage to children covered by Medicaid or other insurance programs; Temporary Assistance for Needy Families, a program that provides assistance to low-income families with children; and Supplementary Security Income, a federal income supplement program, which offers assistance to aged, blind, and disabled individuals who have little or no income. In addition, it provides FamilyCare, a Medicaid expansion health insurance program created to help low income uninsured families, single adults, and couples without dependent children obtain affordable healthcare coverage; and offers Medicare Advantage, a federal program that provides health care coverage primarily to individuals age 65 or older, as well as to individuals with certain disabilities. AMERIGROUP offers its healthcare services through contracts with primary care physicians, specialists, hospitals, and ancillary providers. As of December 31, 2010, it provided an array of products to approximately 1,931,000 members in Texas, Georgia, Florida, Tennessee, Maryland, New Jersey, New York, Nevada, Ohio, Virginia, and New Mexico. The company, formerly known as AMERICAID Community Care, was founded in 1994 and is headquartered in Virginia Beach, Virginia.

HOSPIRA INC (NYSE:HSP) - Hospira, Inc., a specialty pharmaceutical and medication delivery company, develops, manufactures, and markets pharmaceuticals and medication delivery systems in the United States and internationally. It offers generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems for hospitals, wholesalers, integrated delivery networks, and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company primarily provides specialty injectable pharmaceutical products that consist of generic injectable pharmaceuticals for analgesia, anesthesia, anti-infective, cardiovascular, and oncology therapeutic areas, as well as Precedex (dexmedetomidine HCl), a proprietary sedative. Its proprietary drug delivery options include Carpuject and iSecure prefilled syringes, Ansyr prefilled needleless emergency syringe systems, First Choice ready-to-use premixed formulations, and the ADD-Vantage System for preparing drug solutions from prepackaged drug powders or concentrates. The company also offers infusion therapy solutions and supplies that include I.V. solutions for general use; and I.V. nutrition products and solutions for the washing and cleansing of wounds or surgical sites. In addition, it provides medication management systems that include electronic drug delivery pumps, safety software, and administration sets that are used to deliver I.V. fluids and medications. Further, the company offers gravity administration sets, formulation development, and injectable and oral drug filling and finishing services. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

NEKTAR THERAPEUTICS (NASDAQ:NKTR) - Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. The companys product pipeline consists of drug candidates across various therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. Its research and development activities involve small molecule drugs, peptides, and other potential biologic drug candidates. The companys proprietary drug candidates in clinical development comprise NKTR-118, a peripheral opioid antagonist, which has completed Phase II clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase II clinical trail to treat gram-negative pneumonias; NKTR-102, a topoisomerase I inhibitor-polymer conjugate, which is in Phase II clinical trail for multiple cancer indications, including breast, ovarian, and colorectal; and NKTR-105 that is in Phase I clinical trail to treat solid tumors. Its preclinical products consists of NKTR-119 (Opioid/NKTR-118 combinations) for the treatment of pain; NKTR-181 (abuse deterrent, tamper-resistant opioid) to treat pain; NKTR-194 (non-scheduled opioid) for the treatment of mild to moderate pain; NKTR-171 (tricyclic antidepressant) to treat neuropathic pain; and NKTR-140 (protease inhibitor candidate) to treat HIV. The company has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. In addition, Nektar Therapeutics has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, Baxter, Roche, Merck, Pfizer, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.

AETNA INC (NYSE:AET) - Aetna Inc. operates as a diversified health care benefits company in the United States. It offers a range of health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life, and disability plans, as well as medical management capabilities and Medicaid health care management. The company operates in three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment provides medical, pharmacy benefits management, dental, behavioral health, and vision plans. This segments medical products comprise point of service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and Aetna HealthFund. This segment also provides Medicare and Medicaid products and services; and specialty products, such as medical management and data analytics services, medical stop loss insurance, and products that offer access to its provider networks. The Group Insurance segment provides life insurance products that consist of group term life insurance, voluntary spouse and dependent term life insurance, group universal life, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which offer benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. This segment provides insurance products principally to employers that sponsor its products for the benefit of their employees and their employees dependents. The Large Case Pension segment manages various retirement products, including pension and annuity products for tax qualified pension plans. It primarily serves employer groups, individuals, college students, part-time and hourly workers, health plans, governmental units, government-sponsored plans, labor groups, and expatriates. The company was founded in 1982 and is based in Hartford, Connecticut.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641